# Oncolytics Biotech Inc: financial statements, quarterly

ONCY · Nasdaq · CIK 1129928 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oncy.md) · [Financials](/companies/oncy/financials.md) · [Filings](/companies/oncy/filings.md) · [Insiders](/companies/oncy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oncy/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $k | [2,800](/filings/0001129928-26-000033.md) | [1,916](/filings/0001129928-26-000051.md) | [4,552](/filings/0001129928-26-000033.md) | [4,262](/filings/0001129928-26-000051.md) |
| Operating income | $k | [(5,021)](/filings/0001129928-26-000033.md) | [(4,651)](/filings/0001129928-26-000051.md) | [(9,281)](/filings/0001129928-26-000033.md) | [(9,379)](/filings/0001129928-26-000051.md) |
| Income tax | $k | not reported | [61.0](/filings/0001129928-26-000051.md) | not reported | [101](/filings/0001129928-26-000051.md) |
| Net income | $k | [(4,711)](/filings/0001129928-26-000033.md) | [(5,277)](/filings/0001129928-26-000051.md) | [(9,243)](/filings/0001129928-26-000033.md) | [(9,442)](/filings/0001129928-26-000051.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001129928-26-000033.md) | [(0.06)](/filings/0001129928-26-000051.md) | [(0.08)](/filings/0001129928-26-000033.md) | [(0.08)](/filings/0001129928-26-000051.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0001129928-26-000033.md) | [(0.06)](/filings/0001129928-26-000051.md) | [(0.08)](/filings/0001129928-26-000033.md) | [(0.08)](/filings/0001129928-26-000051.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.7](/filings/0001129928-22-000017.md) | [14.1](/filings/0001129928-23-000008.md) | [31.2](/filings/0001129928-24-000018.md) | [41.3](/filings/0001129928-25-000019.md) | [11.7](/filings/0001129928-25-000019.md) | [34.9](/filings/0001129928-25-000019.md) | [11.1](/filings/0001129928-26-000020.md) | not reported | not reported | [5.2](/filings/0001129928-26-000051.md) | [5.5](/filings/0001129928-26-000033.md) | [4.1](/filings/0001129928-26-000051.md) |
| Current assets | $m | [14.5](/filings/0001129928-20-000012.md) | [18.9](/filings/0001129928-21-000013.md) | [33.7](/filings/0001129928-22-000017.md) | [44.9](/filings/0001129928-23-000008.md) | [35.7](/filings/0001129928-24-000018.md) | [38.2](/filings/0001129928-25-000019.md) | [12.4](/filings/0001129928-26-000020.md) | not reported | not reported | [6.8](/filings/0001129928-26-000051.md) | [7.5](/filings/0001129928-26-000033.md) | [7.1](/filings/0001129928-26-000051.md) |
| Total assets | $m | [14.9](/filings/0001129928-20-000012.md) | [19.7](/filings/0001129928-21-000013.md) | [34.3](/filings/0001129928-22-000017.md) | [45.9](/filings/0001129928-23-000008.md) | [37.3](/filings/0001129928-24-000018.md) | [38.8](/filings/0001129928-25-000019.md) | [13.4](/filings/0001129928-26-000020.md) | not reported | not reported | [7.6](/filings/0001129928-26-000051.md) | [8.2](/filings/0001129928-26-000033.md) | [7.7](/filings/0001129928-26-000051.md) |
| Current liabilities | $m | [2.8](/filings/0001129928-20-000012.md) | [12.9](/filings/0001129928-21-000013.md) | [2.7](/filings/0001129928-22-000017.md) | [2.7](/filings/0001129928-23-000008.md) | [3.9](/filings/0001129928-24-000018.md) | [4.2](/filings/0001129928-25-000019.md) | [4.9](/filings/0001129928-26-000020.md) | not reported | not reported | [6.1](/filings/0001129928-26-000051.md) | [5.4](/filings/0001129928-26-000033.md) | [5.2](/filings/0001129928-26-000051.md) |
| Total liabilities | $m | [8.7](/filings/0001129928-20-000012.md) | [19.8](/filings/0001129928-21-000013.md) | [9.6](/filings/0001129928-22-000017.md) | [9.8](/filings/0001129928-23-000008.md) | [10.8](/filings/0001129928-24-000018.md) | [11.3](/filings/0001129928-25-000019.md) | [10.1](/filings/0001129928-26-000020.md) | not reported | not reported | [11.4](/filings/0001129928-26-000051.md) | [13.3](/filings/0001129928-26-000033.md) | [13.8](/filings/0001129928-26-000051.md) |
| Shareholders' equity | $m | [6.2](/filings/0001129928-22-000017.md) | [(0.1)](/filings/0001129928-23-000008.md) | [24.8](/filings/0001129928-24-000018.md) | [36.1](/filings/0001129928-25-000019.md) | [26.5](/filings/0001129928-25-000019.md) | [19.6](/filings/0001129928-26-000020.md) | [3.3](/filings/0001129928-26-000051.md) | [3.7](/filings/0001129928-26-000051.md) | [3.7](/filings/0001129928-26-000051.md) | [(3.8)](/filings/0001129928-26-000051.md) | [(5.1)](/filings/0001129928-26-000051.md) | [(6.2)](/filings/0001129928-26-000051.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: ifrs-full:CurrentAssets, us-gaap:AssetsCurrent
- Total assets: ifrs-full:Assets, us-gaap:Assets
- Current liabilities: ifrs-full:CurrentLiabilities, us-gaap:LiabilitiesCurrent
- Total liabilities: ifrs-full:Liabilities, us-gaap:Liabilities
- Shareholders' equity: ifrs-full:Equity, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,733)](/filings/0001129928-26-000033.md) | [(4,106) d](/filings/0001129928-26-000051.md) | [(7,293)](/filings/0001129928-26-000033.md) | [(8,138) d](/filings/0001129928-26-000051.md) |
| Capital expenditure | $k | [1.0](/filings/0001129928-26-000033.md) | [0.0 d](/filings/0001129928-26-000051.md) | [6.0](/filings/0001129928-26-000033.md) | [0.0 d](/filings/0001129928-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [84.6](/filings/0001129928-26-000033.md) | [91.0](/filings/0001129928-26-000051.md) | [112](/filings/0001129928-26-000033.md) | [120](/filings/0001129928-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 127,510,505 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001129928-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.